Association of Higher Ocrelizumab Exposure With Reduced Disability Progression in Multiple Sclerosis.

ABSTRACT:

Background and objectives

Ocrelizumab improved clinical and MRI measures of disease activity and progression in three phase 3 multiple sclerosis (MS) studies. Post hoc analyses demonstrated a correlation between the ocrelizumab serum concentration and the degree of blood B-cell depletion, and body weight was identified as the most influential covariate on ocrelizumab pharmacokinetics. The magnitude of ocrelizumab treatment benefit on disability progression was greater in lighter vs heavier patients. These observations suggest that higher ocrelizumab serum levels provide more complete B-cell depletion and a greater delay in disability progression. The current post hoc analyses assessed population exposure-efficacy/safety relationships of ocrelizumab in patients with relapsing and pr

SUBMITTER: Hauser SL 

PROVIDER: S-EPMC9931184 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature